Helicobacter Pylori (H. pylori) Infection Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | Phathom Pharmaceuticals, Redhill Biopharma, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, AbbVie, Cumberl

DelveInsight's "Helicobacter Pylori (H. pylori) Infection - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Helicobacter Pylori (H. pylori) Infection market share of the individual therapies, current and forecasted Helicobacter Pylori (H. pylori) Infection market size from 2020 to 2034 segmented by seven major markets. The report also offers current Helicobacter Pylori (H. pylori) Infection therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Helicobacter Pylori (H. pylori) Infection market.
To know more about the report, visit: https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Helicobacter Pylori (H. pylori) Market Report:
Key companies working in the market are Phathom Pharmaceuticals, Redhill Biopharma, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, AbbVie, Cumberland Pharmaceuticals, Pernix Therapeutics, Eisai Co, and others.
The geographic variation in H. pylori infection prevalence can be attributed to factors such as sanitation, urban versus rural lifestyles, socioeconomic status, differences in H. pylori strains, and patterns of antibiotic use.
The H. pylori infection market is projected to experience steady growth from 2023 to 2034, driven by an increasing number of cases across the 7MM. In 2022, the US held the largest share of this market, valued at approximately USD 1,064.8 million, with expectations for further growth by 2034.
The US FDA has approved several treatments for H. pylori infection, including NEXIUM and PREVPAC, along with their authorized generics. Cumberland Pharmaceuticals' OMECLAMOX-PAK and AbbVie's PYLERA offer branded versions of clarithromycin triple therapy and bismuth quadruple therapy, respectively. RedHill Biopharma's TALICIA, a rifabutin-based therapy, is widely used as a second-line treatment. Phathom Pharmaceuticals' VOQUEZNA, a P-CAB combination approved in 2022 and reformulated in 2023, is another notable addition to the market.
Current H. pylori treatment focuses on eradicating the bacteria to heal peptic ulcers and prevent relapses. However, the rise in antibiotic resistance poses a global challenge. Triple therapies, which combine antibiotics with proton pump inhibitors or other acid-regulating drugs, are widely recommended in various guidelines.
Among the therapies, clarithromycin triple therapy, a combination of a proton pump inhibitor, clarithromycin, and amoxicillin or metronidazole, remains one of the most commonly used treatments in the US, generating USD 351.0 million in market revenue in 2022.
Advances in research, a deeper understanding of the disease, and technological improvements are expanding clinical knowledge and leading to new therapeutic developments. Emerging therapies, such as TenNor Therapeutics' Rifasutenizole (TNP-2198), which is expected to launch in 2027, show promise with its dual mechanism of action and low risk of resistance, potentially impacting the competitive landscape.

Helicobacter Pylori (H. pylori) Infection Overview
**Helicobacter pylori (H. pylori)** is a spiral-shaped, flagellated Gram-negative bacterium that primarily colonizes the human stomach and sometimes the small intestine. It is one of the most prevalent chronic bacterial infections globally, typically acquired in childhood, though many infected individuals do not show symptoms.

The World Health Organization (WHO) classifies H. pylori as a Class I carcinogen, and it is recognized as a qualifying pathogen under the US FDA GAIN Act. It is a significant risk factor for non-cardia gastric adenocarcinoma and is often linked to chronic gastritis, preneoplastic lesions, and peptic ulcer disease.

Although often asymptomatic, H. pylori infection can lead to symptoms such as abdominal pain, nausea, vomiting, and dyspepsia, which usually manifest after the onset of gastritis or peptic ulcer disease.

H. pylori is transmitted through fecal-oral, gastric-oral, oral-oral, or sexual routes, with its prevalence varying significantly by region. It is more common in developing and resource-limited countries compared to developed nations, influenced by factors such as climate, host-microbe interactions, genetics, gastrointestinal microbiota, and access to healthcare.
Get detailed insights on helicobacter pylori infection, causes, signs and symptoms, diagnosis, treatment, visit: https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Helicobacter Pylori (H. pylori) Infection Epidemiological Insights
In 2022, the total diagnosed prevalent cases of Helicobacter pylori infection across the 7MM were estimated at approximately 321,217,226. The United States accounted for about 37% of these cases, the EU4 and the UK together represented nearly 43%, and Japan made up approximately 20%.
In the US, there were around 118,650,370 diagnosed cases of Helicobacter pylori infection in 2022, with the number expected to rise due to increased disease awareness and improved diagnostic practices.
The EU4 and the UK collectively reported approximately 138,397,508 diagnosed cases in 2022, with anticipated changes in the number of cases throughout the study period (2020-2034). Among these, France had the highest number of diagnosed cases, accounting for about 23%, followed by Germany and Italy, while the UK reported the fewest cases.
According to DelveInsight's epidemiology model, Helicobacter pylori infection is more prevalent in males than females in the US. In 2022, approximately 52% of the diagnosed cases were in males and 48% in females.
Helicobacter Pylori (H. pylori) Infection Treatment Market
Helicobacter pylori (H. pylori) infection is one of the most prevalent chronic bacterial infections globally, affecting approximately half of the world's population. This spiral-shaped, flagellated gram-negative bacterium primarily colonizes the stomach and small intestine. Typically acquired in childhood, H. pylori is the leading risk factor for non-cardia gastric adenocarcinoma, the most common type of gastric cancer, and is also associated with peptic ulcer disease. Diagnosing H. pylori infection involves a combination of invasive and non-invasive methods due to the lack of a single, definitive diagnostic tool. The World Health Organization (WHO) classifies H. pylori as a Class I carcinogen, and it is recognized as a Qualifying Pathogen under the US FDA GAIN Act.

Since the introduction of the first effective therapy in the 1980s, treatment approaches for H. pylori infection have evolved significantly. Current treatment focuses on eradicating the bacteria to heal peptic ulcers and prevent relapses. However, increasing antibiotic resistance poses a significant challenge to effective treatment.

Treatment guidelines generally recommend triple therapy-combining antibiotics with antisecretory agents or proton pump inhibitors (PPIs)-as the first-line approach for eradicating H. pylori. Monotherapy is less effective due to the reduced efficacy of antibiotics in the acidic environment of the stomach. The growing problem of antibiotic resistance further complicates treatment, with only a few antibiotics, such as clarithromycin, amoxicillin, metronidazole, fluoroquinolones (e.g., levofloxacin, norfloxacin), tetracycline, and rifabutin, remaining effective against H. pylori.

Current guidelines emphasize tailoring eradication therapy based on regional clarithromycin resistance rates and local factors affecting infection. Approved therapies vary by region, with different treatments being authorized at different times in different countries.

RedHill Biopharma's TALICIA, a rifabutin-based therapy, is widely used as a second-line treatment and could significantly impact patients with resistance to clarithromycin and metronidazole due to its 8-year market exclusivity.

Phathom Pharmaceuticals' VOQUEZNA, a P-CAB combination therapy, was approved by the US FDA in 2022 and recently reformulated and reintroduced in 2023.

Despite rising antibiotic resistance reducing the effectiveness of current treatments, ongoing updates to treatment guidelines and new FDA approvals are reshaping the H. pylori treatment landscape. Although the pipeline for novel therapies is currently limited, the anticipated entry of TenNor Therapeutics' rifasutenizole (TNP-2198) during the forecast period could bring significant changes to the market.
Helicobacter Pylori (H. pylori) Infection Market Insights:
The market for Helicobacter pylori (H. pylori) infection is poised for positive growth. In 2022, the total market size for H. pylori infection across the 7MM was approximately USD 2,672.5 million, with expectations of an upward trend throughout the forecast period (2023-2034).
In the US, the H. pylori infection market was valued at about USD 1,064.8 million in 2022, and this figure is expected to rise due to increased disease awareness and the introduction of new therapies.
For the EU4 countries and the UK, the market size was approximately USD 1,028.3 million in 2022, representing around 38% of the total market revenue for the 7MM. Among these regions, France led the market with an estimated USD 237.3 million, followed by Germany with approximately USD 221.2 million. The UK had the smallest market share in this group.
In the US, clarithromycin-based triple therapy held the second-largest market share among current treatments, generating about USD 351.0 million in 2022.
Japan, with a market size of approximately USD 579.4 million in 2022, accounted for the second-largest share of the H. pylori infection market among the 7MM and is expected to see significant growth by 2034.
Promising Therapies in the Helicobacter Pylori (H. pylori) Infection Pipeline
Vonoprazan
K-Cab
And others
Discover more about Helicobacter Pylori (H. pylori) Infection therapies in the pipeline @ https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Helicobacter Pylori (H. pylori) Infection Market
Phatom Pharma
CJ HealthCare
And others
To understand key companies related to the Helicobacter Pylori (H. pylori) Infection Market, get a snapshot of the Helicobacter Pylori (H. pylori) Infection Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Helicobacter Pylori (H. pylori) Infection Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Helicobacter Pylori (H. pylori) Infection Companies: Phatom Pharma, CJ HealthCare, and others
Key Helicobacter Pylori (H. pylori) Infection Pipeline Therapies: Vonoprazan, K-Cab, and others
Therapeutic Assessment: Helicobacter Pylori (H. pylori) Infection current marketed and emerging therapies
Helicobacter Pylori (H. pylori) Infection Market Dynamics: Helicobacter Pylori (H. pylori) Infection market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Helicobacter Pylori (H. pylori) Infection Market Access and Reimbursement
Table of Contents
1. Helicobacter Pylori (H. pylori) Infection Market Key Insights
2. Helicobacter Pylori (H. pylori) Infection Market Report Introduction
3. Helicobacter Pylori (H. pylori) Infection Market Overview at a Glance
4. Helicobacter Pylori (H. pylori) Infection Market Executive Summary
5. Disease Background and Overview
6. Helicobacter Pylori (H. pylori) Infection Treatment and Management
7. Helicobacter Pylori (H. pylori) Infection Epidemiology and Patient Population
8. Patient Journey
9. Helicobacter Pylori (H. pylori) Infection Emerging Drugs
10. 7MM Helicobacter Pylori (H. pylori) Infection Market Analysis
11. Helicobacter Pylori (H. pylori) Infection Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Helicobacter Pylori (H. pylori) Infection Market Drivers
15. Helicobacter Pylori (H. pylori) Infection Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.